Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis.

BMJ Open Respir Res · 2015 · PMC4680008 · PMID 26688732

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Both ciprofloxacin DPI arms transiently showed nominally significant results of reduced total bacterial load ( P. aeruginosa ) up to day 15 compared with matching placebo arms.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.